Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1992 1
1997 1
2007 1
2011 3
2012 3
2013 1
2014 2
2015 1
2016 2
2017 5
2018 3
2019 2
2020 8
2021 5
2022 6
2023 7
2024 5
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Merryman RW, et al. Blood Adv. 2020 Mar 10;4(5):858-867. doi: 10.1182/bloodadvances.2019001355. Blood Adv. 2020. PMID: 32126141 Free PMC article.
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.
Looka A, Qualls DA, Matthews D, Redd RA, Sakellis C, Duffy C, Dela Cruz J, Saucier A, Armand P, Crombie JL, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Merryman RW, Parry EM, Jacobson CA. Looka A, et al. Among authors: merryman rw. Blood Adv. 2025 Feb 11;9(3):455-462. doi: 10.1182/bloodadvances.2024012992. Blood Adv. 2025. PMID: 39546746 Free PMC article.
Improved survival in cHL with novel agents.
Merryman RW, LaCasce AS. Merryman RW, et al. Blood. 2023 Jun 1;141(22):2666-2668. doi: 10.1182/blood.2023020068. Blood. 2023. PMID: 37261856 Free article. No abstract available.
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.
Falchi L, Sureda A, Leppä S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D. Falchi L, et al. Among authors: merryman rw. Blood. 2025 Nov 27;146(22):2629-2640. doi: 10.1182/blood.2025029909. Blood. 2025. PMID: 40920572 Free article. Clinical Trial.
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M. Shadman M, et al. Among authors: merryman r. Blood Cancer J. 2024 Jul 8;14(1):108. doi: 10.1038/s41408-024-01084-w. Blood Cancer J. 2024. PMID: 38977682 Free PMC article.
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.
Frigault MJ, Yao N, Berger TR, Wehrli M, Gallagher KME, Horick N, Graham CE, Jacobson CA, Chen YB, Leick MB, DeFilipp Z, El-Jawahri AR, Johnson PC, Dolaher M, Katsis K, Kim AI, Crombie J, Merryman RW, Cook D, Trailor M, Cho H, Jeffrey R 3rd, Shen R, Filosto S, Nater J, Getz G, Haradhvala NJ, Maus MV. Frigault MJ, et al. Among authors: merryman rw. Blood Adv. 2025 May 13;9(9):2122-2135. doi: 10.1182/bloodadvances.2024015161. Blood Adv. 2025. PMID: 39928957 Free PMC article. Clinical Trial.
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.
Yoon JT, Zhou Y, Mikhaleva M, Choi DS, Fernandes SM, Armand P, Bessnow AC, Crombie JL, Fisher DC, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Merryman RW, Odejide OO, Parry EM, Qualls DA, Ryan CE, Sekar A, Soumerai JD, Arnason J, Tyekucheva S, Davids MS, Brown JR, Ahn IE. Yoon JT, et al. Among authors: merryman rw. Blood Adv. 2025 Jun 10;9(11):2808-2817. doi: 10.1182/bloodadvances.2025016006. Blood Adv. 2025. PMID: 40179394 Free PMC article.
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma.
Krasnow N, Maurer K, Song C, Rhoades J, Xiong K, Crnjac A, Blewett T, Gao L, Jacene H, Merryman R, Gohil SH, Duffy C, Guerrero LI, Dela Cruz J, McDonough M, Wolff JO, Redd R, Mattie M, Miles B, Makrigiorgos GM, Neuberg DS, Rodig SJ, Armand P, Jacobson C, Adalsteinsson VA, Wu CJ. Krasnow N, et al. Among authors: merryman r. Blood Adv. 2025 Nov 11;9(21):5539-5545. doi: 10.1182/bloodadvances.2024015788. Blood Adv. 2025. PMID: 40706054 Free article.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Merrill MH, Dahi PB, Redd RA, McDonough MM, Chen YB, DeFilipp Z, Herrera AF, Fisher DC, LaCasce AS, Odejide OO, Ng SY, Jacobson CA, Merryman RW, Kim AI, Nieto YL, Sauter CS, Shah GL, Zain JM, Armand P, Jacobsen ED. Merrill MH, et al. Among authors: merryman rw. Blood. 2023 Aug 17;142(7):621-628. doi: 10.1182/blood.2023020244. Blood. 2023. PMID: 37319432 Free PMC article. Clinical Trial.
61 results